Navigation Links
Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
Date:10/22/2010

SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that the Company will host a webcast conference call Monday afternoon, October 25, 2010 at 4:00 p.m. Eastern time to provide a corporate update. Gregory A. Demopulos, M.D., chairman and chief executive officer, will provide remarks which will be followed by a question and answer session.

To access the live call by telephone, please dial 800-901-5217 (United States and Canada) or 617-786-2964 (International). The passcode is 26273994.  In addition, the live conference call will be webcast and can be accessed on the "Events" page of the Company's website at http://www.omeros.com.

A replay of the webcast will be available on the Company's website for one week.  A telephone replay will also be available for one week starting at 7:00 p.m. Eastern time on October 25, which can be accessed by dialing 888-286-8010 (United States and Canada) or 617-801-6888 (International) and entering passcode 82437761.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery(TM) platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Omeros to Present at the BioCentury NewsMakers Conference
2. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
3. Omeros Successfully Unlocks Orphan GPCRs
4. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
5. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
6. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
7. Daniel K. Spiegelman Elected to Board of Directors of Omeros
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
10. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
11. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sony Biotechnology Inc. ("Sony") today announced the launch of the ... chip.  Sony will also be exhibiting its newly rebranded reagent ... the EC800 flow cytometer, and new SP6800 Spectral Analyzer will ... be held at the San Diego ... from May 20 - 22.  The 8-well ...
(Date:5/17/2013)... , May 17, 2013  TechAtlas Group ... for their competitive landscape map for the Chronic ... over 90 international companies with drugs and devices ... CKD and its sequelae. (Logo:  ... , hypertension - renal denervation ...
(Date:5/17/2013)... LAKES, Fla. , May 17, 2013 Fuse ... and delivery technology company that is developing new, patent-pending technologies ... minerals, announced today that it will hold a business update ... Wednesday, May 22 nd , 2013 at 4:30 PM ET. ... Tuffin will host the call and will be ...
Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2
... -- China Health Resource, Inc. (OTCBB: CHRI), today announced results ... the first quarter of 2012. Revenues for ... increase of 234% over revenues of US $10,282,207 for 2010. For ... common share, compared with a net income of $2,707,286, or ...
... Oncos Therapeutics today announced the successful initiation ... adenovirus suggested as a potential new treatment for many types ... safety assessment part of the study. " We ... r thern Europe to start a clinical study with ...
Cached Medicine Technology:China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012 2China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012 3Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & ... market drivers, restraints, and opportunities in North America, Europe, ... 89 market data tables , ... IT Market" , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , ... The global healthcare IT market is expected to grow ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 TheBeautyPlace.com answers ... Pattern hair loss is not a result of stress, ... to Men’s Fitness Magazine, 70% of men suffer from ... Strength is renowned for hair transplant surgery, but ... male pattern baldness known as Bosley Professional Strength. Their ...
(Date:5/18/2013)... Family Magazine of Washington DC was awarded the "Best ... Inc. in the category of Summer Camps in DC ... the areas best in the ultimate guide on parenting, kids ... Brenda Hyde, a mother of four and publisher of Family ... vast resources available to them in the DC Metro area. ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... mount in courts throughout the country, Bernstein Liebhard LLP ... hip replacement patients often suffer tissue damage before they ... study, which according to Science Daily will appear in ... hip replacement recipients underwent MRI screens of their hips. ...
Breaking Medicine News(10 mins):Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4
... 29, 2009) The allergen breathed in by a person ... activates a cascade of events to prompt an allergic reaction, ... Medicine ( www.bcm.edu ) in Houston in a report that ... , In particular, MMP7 activates interleukin 25, a key mediator ...
... shortness of breath and trimmed hospital stays, phase 2 study ... relaxin reduces shortness of breath and cardiovascular death in people ... to a phase 2 trial conducted in eight countries. ... hours of arriving at a hospital, were randomly assigned to ...
... to clean equipment regularly with alcohol wipes , , ... three stethoscopes used by U.S. emergency medical service ... bacteria, a new study suggests. , Researchers at ... Jersey swabbed 50 stethoscopes used by independent emergency ...
... recently reported on new Baxter Heparin testing standards that are to ... following several deaths after the contaminated drug was used on patients, ... an ingredient that caused the deaths of several and sickened hundreds. ... ...
... M.D., MPH, co-director of the National Center for Vermiculite ... Cancer Institute in Detroit, MI, and chief of the ... University , announced the use of a new technology ... The announcement was made at the Asbestos Disease Awareness ...
... In what has quickly evolved into a historic ... in Northwestern Minnesota and Eastern North Dakota, is ... the region. Despite rising flood waters and disrupted ... are still accepting patients, according to officials. To ...
Cached Medicine News:Health News:Hormone Reduces Mortality in Heart Patients With High BP 2Health News:Third of EMS Stethoscopes Carry MRSA Bacterium 2Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 2Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 3Health News:LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination 4Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 3Health News:Innovis Health Continues to Serve Region 2
Provides a combination of concentrated cold / hot and compression for the neck...
Provides a combination of concentrated cold / hot and compression for the back...
... One-Piece™ Collar is completely injected molded from ... our patented chin support. , ,Our ... efficiently managed where space is limited. Color-coded ... of sizes., ,Either in a supine ...
... optional hot and cold therapy Gel Pad. Our ... providing cold therapy to reduce swelling and /or ... recovery., ,To order hot and cold therapy ... number., ,Our suspenders can be added to ...
Medicine Products: